Hofseth Biocare ASA (HBC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hofseth Biocare ASA (HBC) has a cash flow conversion efficiency ratio of 0.167x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-4.65 Million ≈ $-489.52K USD) by net assets (Nkr-27.85 Million ≈ $-2.93 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see HBC market cap overview for the company's overall valuation and market capitalisation.
Hofseth Biocare ASA - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Hofseth Biocare ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Hofseth Biocare ASA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hofseth Biocare ASA ranked by their cash flow conversion efficiency. Explore HBC operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ADAMA Ltd B
SHE:200553
|
0.037x |
|
Impulse Fitness Solutions SA
PA:MLIFS
|
N/A |
|
374Water Inc. Common Stock
NASDAQ:SCWO
|
0.071x |
|
Techbond Group Bhd
KLSE:5289
|
0.028x |
|
Cheche Group Inc. Class A Ordinary Shares
NASDAQ:CCG
|
-0.012x |
|
Hantop Inc
KQ:002680
|
0.055x |
|
Kedoya Adyaraya Tbk PT
JK:RSGK
|
-0.004x |
|
Thai Nippon Rubber Industry Public Co. Ltd
BK:TNR
|
0.025x |
Annual Cash Flow Conversion Efficiency for Hofseth Biocare ASA (2010–2024)
The table below shows the annual cash flow conversion efficiency of Hofseth Biocare ASA from 2010 to 2024. View current stock price of Hofseth Biocare ASA for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Nkr61.30 Million ≈ $6.45 Million |
Nkr-9.78 Million ≈ $-1.03 Million |
-0.160x | -337.71% |
| 2023-12-31 | Nkr41.14 Million ≈ $4.33 Million |
Nkr2.76 Million ≈ $290.54K |
0.067x | +121.99% |
| 2022-12-31 | Nkr148.03 Million ≈ $15.58 Million |
Nkr-45.17 Million ≈ $-4.75 Million |
-0.305x | +30.67% |
| 2021-12-31 | Nkr140.38 Million ≈ $14.77 Million |
Nkr-61.78 Million ≈ $-6.50 Million |
-0.440x | -88.34% |
| 2020-12-31 | Nkr263.76 Million ≈ $27.76 Million |
Nkr-61.63 Million ≈ $-6.49 Million |
-0.234x | +11.42% |
| 2019-12-31 | Nkr117.75 Million ≈ $12.39 Million |
Nkr-31.06 Million ≈ $-3.27 Million |
-0.264x | +20.71% |
| 2018-12-31 | Nkr86.04 Million ≈ $9.05 Million |
Nkr-28.62 Million ≈ $-3.01 Million |
-0.333x | +51.59% |
| 2017-12-31 | Nkr37.08 Million ≈ $3.90 Million |
Nkr-25.48 Million ≈ $-2.68 Million |
-0.687x | +45.24% |
| 2016-12-31 | Nkr53.56 Million ≈ $5.64 Million |
Nkr-67.23 Million ≈ $-7.07 Million |
-1.255x | -612.71% |
| 2015-12-31 | Nkr32.55 Million ≈ $3.42 Million |
Nkr7.97 Million ≈ $838.36K |
0.245x | +131.04% |
| 2014-12-31 | Nkr78.95 Million ≈ $8.31 Million |
Nkr-62.26 Million ≈ $-6.55 Million |
-0.789x | +41.55% |
| 2013-12-31 | Nkr62.00 Million ≈ $6.52 Million |
Nkr-83.65 Million ≈ $-8.80 Million |
-1.349x | -34.11% |
| 2012-12-31 | Nkr47.72 Million ≈ $5.02 Million |
Nkr-48.01 Million ≈ $-5.05 Million |
-1.006x | -522.78% |
| 2011-12-31 | Nkr120.53 Million ≈ $12.68 Million |
Nkr-19.47 Million ≈ $-2.05 Million |
-0.162x | +1.39% |
| 2010-12-31 | Nkr75.97 Million ≈ $7.99 Million |
Nkr-12.45 Million ≈ $-1.31 Million |
-0.164x | -- |
About Hofseth Biocare ASA
Hofseth BioCare ASA produces and sells health nutritional products for humans and pets in Norway, the United Kingdom, France, Belgium, Italy, Germany, rest of Europe, Japan, Asia, and the United States. The company offers ProGo, a bioactive peptide for weight management and metabolic health; OmeGo, a salmon oil that provides a full spectrum of fatty acids and omegas; CalGo and NT-II, which are ca… Read more